Share on StockTwits
 

Zoetis Inc. (NYSE:ZTS) issued an update on its FY14 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.48-1.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.61, ARN reports. The company issued revenue guidance of $4.65-4.75 billion, compared to the consensus revenue estimate of $4.77 billion.

A number of analysts have recently weighed in on ZTS shares. Analysts at Zacks reiterated a neutral rating on shares of Zoetis in a research note on Friday, January 10th. They now have a $34.00 price target on the stock. On a related note, analysts at Morgan Stanley downgraded shares of Zoetis from an overweight rating to an equal weight rating in a research note on Wednesday, January 8th. They now have a $36.00 price target on the stock. Finally, analysts at William Blair initiated coverage on shares of Zoetis in a research note on Monday, November 25th. They set a market perform rating on the stock. Six research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $36.36.

Shares of Zoetis Inc. (NYSE:ZTS) opened at 31.14 on Tuesday. Zoetis Inc. has a 1-year low of $28.81 and a 1-year high of $35.42. The stock’s 50-day moving average is $31.58 and its 200-day moving average is $31.37. The company has a market cap of $15.570 billion and a P/E ratio of 39.46.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 11th. The company reported $0.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.34 by $0.02. The company had revenue of $1.25 billion for the quarter, compared to the consensus estimate of $1.21 billion. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. Analysts expect that Zoetis Inc. will post $1.40 EPS for the current fiscal year.

Zoetis Inc, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.